

PRESS RELEASE

Lund, Sweden, October 20, 2022

Nomination committee appointed for the 2023 Annual General Meeting in Spago Nanomedical

In accordance with a resolution at Spago Nanomedical AB's Annual General Meeting on May 18, 2022, a Nomination Committee for the 2023 Annual General Meeting has been appointed.

The Nomination Committee for the 2023 Annual General Meeting has been established based on the largest owners as of September 30, 2022, who wished to participate in the Nomination Committee's work. The Nomination Committee has the following composition:

- Peter Lindell, represents Cidro Förvaltning AB and own holding
- Mikael Lönn, represents own holding
- Eva Redhe, represents own holding

The Nomination Committee has elected Peter Lindell as Chairman.

The Nomination Committee's assignment is to present proposals for the Annual General Meeting regarding the Chairman of the Annual General Meeting, election of Chairman and other members of the Board, as well as remuneration to each of the Board members. The Nomination Committee shall also submit proposals for the election and remuneration of auditors.

Shareholders who wish to submit proposals to the Nomination Committee can do so by e-mail to: valberedning2023@spagonanomedical.se

For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company's development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical's share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.

FNCA Sweden AB is the Certified Adviser of the company.

Nomination committee appointed for the 2023 Annual General Meeting in Spago Nanomedical